Promising Drug for Endometrial Cancer Shows Strong Results in Trial

A new potential treatment for endometrial cancer has shown encouraging results in a Phase 3 clinical trial. Merck, the drug company, announced on Monday that its investigational drug, sacituzumab tirumotecan (sac-TMT), achieved its primary endpoints of overall survival and progression-free survival in patients with advanced or recurrent endometrial cancer.

The TroFuse-005 trial marks a significant milestone, as it is the first global Phase 3 trial that demonstrated a statistically meaningful improvement in survival compared to traditional chemotherapy for these patients, according to Merck’s press release.

This achievement comes as sac-TMT becomes the first antibody-drug conjugate (ADC) to achieve such results for endometrial cancer patients in this context.

An ADC is a targeted therapy that aims to deliver more of the medication directly to the tumor cells, minimizing harm to healthy cells. The investigational drug sac-TMT is administered every two weeks via intravenous infusion, targeting the tumor more precisely.

The clinical trial involved 776 patients who had experienced disease progression after receiving platinum chemotherapy and immunotherapy. Participants were randomly assigned to receive either sac-TMT or a treatment of the physician’s choice, among options such as doxorubicin or paclitaxel chemotherapy. Patients were informed of their treatment allocation.

Those treated with sac-TMT showed noticeable improvements in their disease status compared to those receiving treatment chosen by physicians, according to researchers. The study met response rate benchmarks and reported similar side effects to previous studies of sac-TMT.

Despite not disclosing specific statistics on survival benefit, response rate, or side effects, researchers aim to present detailed Phase 3 data at an upcoming medical meeting. Dr. Domenica Lorusso, global lead investigator, emphasized that sac-TMT could meet a critical unmet need for certain patients with advanced endometrial cancer.

Dr. Brian Slomovitz, an investigator on the trial and co-director of gynecologic oncology at Mount Sinai, noted in an interview that endometrial cancers and related deaths are increasing in the United States. He remarked that endometrial cancer has become the deadliest gynecologic malignancy, surpassing ovarian cancer in mortality rates.

Despite advances in treatments, including the introduction of immunotherapy as the standard care, patients with recurrent disease still need better options, Slomovitz expressed. The potential overall survival improvement offered by sac-TMT presents a meaningful benefit for patients and their families.